Current Issue

VOL 8 • NO 7 NOV/DEC 2017


Innovations in Cancer Therapies and Rising Costs

Pamela Hallquist Viale, RN, MS, CNS, ANP

It is an exciting time to be caring for patients with cancer. Great strides are being made in the treatment landscape, with new therapies approved seemingly every month. Patients have more opportunities to receive novel and innovative treatments with improved outcomes. These therapies require adv...

Original Research

Psychosocial Distress as a Factor in Patients With Cancer Seeking Support: A Hermeneutic Study

Marjan Mardani-Hamooleh, PhD, and Haydeh Heidari, PhD

Cancer is one of the main causes of human death in the world, but its mortality rates have been in continual decline for the past 20 years (Siegel, Miller, & Jemal, 2015). It is a growing problem in Middle Eastern countries (Daher, 2011). In Iran, an ancient country in the Middle East (Borimn...

Continuing Education

Continuing Education Information: Integrating Biosimilars Into Oncology Practice: Implications for the Advanced Practitioner

Integrating Biosimilars Into Oncology Practice: Implications for the Advanced Practitioner  A continuing education activity for nurse practitioners, PAs, clinical nurse specialists, advanced degree nurses, oncology and hematology nurses, pharmacists, and physicians. Release date: November 16, 201...

Review Article

Integrating Biosimilars Into Oncology Practice: Implications for the Advanced Practitioner

Christopher J. Campen, PharmD, BCOP

Click here for Continuing Education Information. Biologic agents play an increasingly important role in the medical care of patients. Between 2010 and 2015, biologics accounted for 22% of drugs approved by the US Food and Drug Administration (FDA). This comes at a cost, however: Although less th...

Review Article

Managing Tumor Lysis Syndrome in the Era of Novel Cancer Therapies

Ali McBride,(1) PharmD, MS, BCPS, BCOP, Steven Trifilio,(2) RPh, Nadine Baxter,(3) MNSc, APN-BC, AOCNP®, Tara K. Gregory,(4) MD, and Scott C. Howard,(5) MD, MS

Tumor lysis syndrome (TLS) is a potentially life-threatening emergency that can develop rapidly after the release of intracellular contents from lysed malignant cells (Cairo, Coiffier, Reiter, Younes, & TLS Expert Panel, 2010; Howard, Jones, & Pui, 2011; Wilson & Berns, 2014). Charact...

Grand Rounds

Practical Strategies for Management of Lenalidomide-Associated Cytopenias in Myelodysplastic Syndromes With del(5q)

Sandra E. Kurtin,(1) PhDc, ANP-C, AOCN®, Jean A. Ridgeway,(2) DNP, NP-C, AOCN®, and Sara Tinsley,(3) PhD, ARNP, AOCN®

A heterogeneous group of bone marrow (BM) failure disorders, myelodysplastic syndromes (MDS) is common in older adults. Sustained unilineage or multilineage cytopenia is included in the mandatory diagnostic criteria of MDS (Valent et al., 2007). Anemia and transfusion dependence are inevitable in...

Grand Rounds

Symptom Management Strategies for Patients Receiving Anaplastic Lymphoma Kinase Inhibitors for Non–Small Cell Lung Cancer

Jennifer Jacky, MSN, ARNP, and Christina Baik, MD, MPH

Lung cancer is the second most commonly diagnosed cancer in the United States, with an estimated 222,500 new cases in 2017 (American Cancer Society [ACS], 2017). Non–small cell lung cancer (NSCLC), the most common type (Matsuda & Machii, 2015), has a poor prognosis, with a 5-year survival rat...

Practice Matters

Li-Fraumeni Syndrome

Wendy H. Vogel, MSN, FNP, AOCNP®

Li-Fraumeni syndrome is a rare inherited autosomal-dominant disorder that is manifested by a wide range of malignancies that appear at an unusually early age. Li-Fraumeni syndrome is also known as sarcoma, breast, leukemia, and adrenal gland (SBLA) cancer syndrome. This syndrome first appeared in...

Practice Matters

Immunotherapy Through the Years

Jessica Eno, MS, PA-C

Immunotherapy’s use in oncology has emerged in recent years as an important treatment option in many different disease sites, but the concept of immunotherapy has been discussed for centuries. Although the beginning of immunotherapy itself dates back to the 18th century, the principles it is base...

Prescriber's Corner

Lenvatinib in the Treatment of Differentiated Thyroid Cancer and Advanced Renal Cell Carcinoma

Urvi J. Patel, PharmD, MPH, and Megan May, PharmD, BCOP

Differentiated thyroid cancer (DTC) is a malignancy that is occurring with greater frequency. Between the years 2006 and 2010, the incidence increased at an annual rate of 5.4% in men and 6.5% in women (Siegel, Ma, Zou, & Jemal, 2014). Although the prognosis of this cancer is favorable, optim...

Tools and Technology

Hepatitis C Virus in the Hematology/Oncology Patient

Wendy H. Vogel, MSN, FNP, AOCNP®

Hepatitis C virus (HCV) is an acute viral infection of the liver, with symptoms that may include fever, headache, malaise, anorexia, nausea, vomiting, diarrhea, and abdominal pain and either jaundice or elevated serum alanine aminotransferase (ALT) levels of > 400 IU/L (Centers for Disease Pre...


Oral Cancer Therapy: The Importance of Adherence

When people think of cancer treatment, they frequently picture patients receiving intravenous (IV) treatments over several hours in a hospital or clinic setting. But over the past 2 decades, more and more cancer treatments that can be taken at home—in tablet, capsule, or liquid form—have become ...


The SMARTIE Program: A Novel Initiative to Evaluate the Impact of AP Continuing Education on Clinical Practice

Sandra E. Kurtin,(1) PhDc, ANP-C, AOCN®, Constance Visovsky,(2) PhD, RN, ACNP-BC, Erik D. Brady,(3) PhD, CHCP, and Alana L. K. Brody,(4) MBA, CHCP

The landscape of cancer care in the United States continues to undergo numerous shifts and innovations, with notable progress in drug development and technologies, resulting in improved progression-free and overall survival for many cancer diagnoses (American Society of Clinical Oncology [ASCO], ...



Section Seperator
Section Seperator
Section Seperator
Section Seperator
Copyright © 2016 Harborside Press, LLC All rights reserved.                Home | Current Issue | Previous Issue | Submissions | About JADPRO | Advertising | Privacy Policy | Contact
Copyright Notice/Disclaimer
Bot trap - Don't go here